Press Releases PTC Therapeutics, Inc.

Equities

PTCT

US69366J2006

Real-time Estimate Cboe BZX Other stock markets 10:39:32 2024-05-08 am EDT			5-day change	1st Jan Change
31.24 ^USD	-1.71%		-8.71%	+13.15%

Apr. 30	North American Morning Briefing : More Earnings -2-	DJ
Apr. 29	Morgan Stanley Upgrades PTC Therapeutics to Equalweight From Underweight, Adjusts PT to $30 From $28	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

PTC Therapeutics : Corporate Presentation – May 2024	May. 03	PU
PTC Therapeutics to Participate at Upcoming Investor Conferences	May. 02	PR
PTC Therapeutics : Q1 2024 FLS	Apr. 25	PU
PTC Therapeutics: Q1 Earnings Snapshot	Apr. 25	AQ
PTC Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results	Apr. 25	PR
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)	Apr. 24	AQ
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Apr. 23	PR
PTC Therapeutics to Host Conference Call to Discuss First Quarter 2024 Financial Results	Apr. 12	AQ
PTC Therapeutics to Host Conference Call to Discuss First Quarter 2024 Financial Results	Apr. 11	PR
PTC Announces Submission of Sepiapterin MAA for Treatment of PKU to EMA	Mar. 28	PR
ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza as a Treatment for AADC Deficiency	Mar. 20	AQ
PTC Therapeutics Provides Key Regulatory Updates	Mar. 19	PR
PTC Therapeutics: Q4 Earnings Snapshot	Feb. 29	AQ
PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results	Feb. 29	PR
PTC Therapeutics to Participate at Upcoming Investor Conferences	Feb. 27	PR
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Feb. 22	PR
Diffuse Intrinsic Pontine Glioma Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2024 (Updated)	Feb. 21	AQ
PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results	Feb. 15	PR
PTC Therapeutics - CHMP Issues Negative Opinion for Renewal of Conditional Marketing Authorization for Translarna Following Re-examination Procedure	Jan. 26	AQ
CHMP Issues Negative Opinion for Renewal of Conditional Marketing Authorization for Translarna™ (ataluren) Following Re-examination Procedure	Jan. 25	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases PTC Therapeutics, Inc.

Equities

PTCT

US69366J2006

Press Releases

Filters